Canrenone Effects on Cardiovascular Mortality in Patients With Congestive Heart Failure (the Coffee-it Study)
NCT ID: NCT03263962
Last Updated: 2018-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
502 participants
OBSERVATIONAL
2017-07-13
2017-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure
NCT00259038
A Study of CK-1827452 Infusion in Stable Heart Failure
NCT00624442
Effects of Dietary Nitrate Supplementation on Cardiorespiratory Control in Chronic Heart Failure
NCT02401126
Safety Study of CD-NP in Heart Failure
NCT00557661
Daptomycin Concentration in Drainage Fluid and Blood Samples of ICU Patients
NCT03004066
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators will evaluate the effects of an aldosterone antagonist as canrenone compared to a group without canrenone and the investogators will verify how many patients reported cardiovascular mortality or will survive.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
With canrenone
Patients with canrenone
Canrenone
Evaluation of canrenone therapy in patients with CHF
Without canrenone
Patients without canrenone
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Canrenone
Evaluation of canrenone therapy in patients with CHF
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* preserved systolic function (FE ≥ 45%)
Exclusion Criteria
* patients with impaired systolic function (FE \< 45%)
* history of active hepatitis or cirrhosis
* impaired renal function
* hyperpotassemia
* diabetes
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Pavia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Giuseppe Derosa
MD, PhD, FESC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS Policlinico San Matteo
Pavia, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20170016069
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.